This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0022858337 Reproduction Date:
InChI=1S/C18H20INO4/c1-21-16-9-14(19)17(22-2)8-12(16)6-7-20-10-13-4-3-5-15-18(13)24-11-23-15/h3-5,8-9,20H,6-7,10-11H2,1-2H3 Y Key:NJNMIPDEUMTYNV-UHFFFAOYSA-N Y
25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT2A receptor with a Ki of 0.049nM at the human 5HT2A receptor.[1][2][3] The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT2A receptor.[4] Common doses are reported to be between 500 µg and 1.5 mg. Although the low end of the dose response curve is similar to LSD, being active at 500 µg, some reports show 1.5–2.0 mg being a low dose, making it up to four times less active than its nbome counterpart 25I-NBOMe. As a recreational drug, 25I-NBMD has not been on the open market for long; therefore there are very few reports about its use.
Amphetamine, Cocaine, Iron, Zinc, Methamphetamine
5-Methoxytryptamine, Metitepine, Lysergic acid diethylamide, Bromocriptine, Methysergide
5-Carboxamidotryptamine, Metitepine, Lysergic acid diethylamide, Bromocriptine, Methysergide
Dark matter, Rice University, Italy, Columbia University, Gran Sasso National Laboratory
Lysergic acid diethylamide, 5-Carboxamidotryptamine, 5-Methoxytryptamine, Metitepine, Xenon
Ergoline, Serotonin, Lysergic acid diethylamide, 5-Methoxytryptamine, Methysergide
Ergoline, Serotonin, Lysergic acid diethylamide, 5-Methoxytryptamine, Substituted tryptamine